What is Rifaximin?
Rifaximin is a non-absorbable, oral broad-spectrum antibiotic with activity against both gram-positive and gram-negative aerobic and anaerobic bacteria, FDA-approved for treating irritable bowel syndrome with diarrhea (IBS-D), travelers' diarrhea, and hepatic encephalopathy (HE) in patients with liver cirrhosis. 1, 2
Mechanism of Action
Rifaximin is a semi-synthetic derivative of rifampin that works by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, blocking transcription and inhibiting bacterial protein synthesis 2. Its key distinguishing feature is minimal gastrointestinal absorption (less than 0.4% systemic bioavailability), which allows it to maintain high concentrations in the intestinal lumen while minimizing systemic side effects 3, 4.
FDA-Approved Indications and Dosing
IBS-D (Irritable Bowel Syndrome with Diarrhea)
- Dose: 550 mg three times daily for 14 days 1
- Retreatment: Patients who experience symptom recurrence can be retreated up to 2 times with the same dosage regimen 1
- Efficacy: Improves global IBS symptoms, bloating, stool consistency, and abdominal pain compared to placebo, though effects on pain may be modest 1, 5
Travelers' Diarrhea
- Dose: 200 mg three times daily for 3 days 2
- Target pathogens: Primarily effective against enterotoxigenic and enteroaggregative E. coli 2
- Limitation: Less effective for invasive pathogens (Campylobacter, Salmonella, Shigella) and should not be used for dysentery 6
Hepatic Encephalopathy
- Dose: 550 mg twice daily (or 400 mg three times daily) 7, 8
- Use: Secondary prophylaxis following overt HE episodes, typically combined with lactulose 8, 9
- Efficacy: Reduces HE recurrence and rehospitalization rates when added to lactulose therapy 7, 10
Unique Pharmacological Properties
Beyond its antimicrobial effects, rifaximin exhibits several distinctive mechanisms 11, 12:
- Pregnane X receptor (PXR) agonism: Modulates intestinal inflammation and barrier function through nuclear receptor activation
- Anti-inflammatory effects: Reduces gut mucosal inflammation independent of bacterial killing
- Minimal microbiome disruption: Unlike systemic antibiotics, causes limited alterations to overall gut microbiota composition
- Gut-liver axis modulation: Reduces bacterial translocation and systemic inflammation in cirrhosis 3
Safety Profile
Rifaximin has a highly favorable safety profile due to minimal systemic absorption 1, 5, 4:
- Common side effects: Headache (most frequent), but overall adverse event rates similar to placebo 1, 5
- No significant drug interactions: Does not meaningfully affect CYP3A4 activity or oral contraceptive efficacy 2
- Low risk of C. difficile infection: Substantially lower than systemic antibiotics 1
Critical Caveat: Antibiotic Resistance
A major emerging concern is the development of high-level rifaximin resistance with long-term use. A 2025 prospective study found that 67% of cirrhosis patients on chronic rifaximin therapy (median 22 weeks) developed high-level rifaximin-resistant intestinal E. coli, compared to only 12% of controls 13. This resistance shows complete cross-resistance to rifampicin and may limit rifaximin's utility for preventing spontaneous bacterial peritonitis in cirrhosis patients, though its effectiveness for HE prevention appears maintained 13, 14.
Clinical Context
Rifaximin represents a unique therapeutic option because it combines antimicrobial activity with immunomodulatory properties while remaining largely confined to the gastrointestinal tract. The 2022 AGA guidelines position it as a second-line agent for IBS-D 1, while the 2021 British Society of Gastroenterology guidelines note its modest efficacy and limited effect on abdominal pain compared to other agents like 5-HT3 antagonists 5. For hepatic encephalopathy, it is recommended as adjunctive therapy to lactulose after recurrent episodes 8, 9.
The drug's bile solubility makes it particularly active in the small bowel, while its low water solubility limits activity in the colon primarily to highly susceptible anaerobes 15. This unique pharmacokinetic profile contributes to its sustained effects in non-infectious diseases like IBS-D and HE, where gut microbiota modulation and anti-inflammatory properties appear as important as direct antimicrobial action 11, 15, 12.